Automated benchtop systems are beginning to integrate oligonucleotide synthesis and protein production. Given economic pressures to innovate in drug manufacture and the potential of platform production technologies to enable decentralization, a future in which the brand manufacturers’ monopoly on biologics could be broken is feasible.
Access to conjugate vaccines is limited due to centralized production and cold chain distribution requirements. To combat these challenges, researchers developed a modular technology for in vitro bioconjugate vaccine expression in portable, freeze-dried lysates.
The biopharma industry has not defined preferred approaches, technologies, or protocols for viral safety in continuous manufacturing operations.
An innovative new technology developed by Fraunhofer researchers will use electron beams to produce inactivated vaccines quickly, reproducibly and without the use of chemicals.
Researchers are developing methods with which viruses for vaccines can be replicated in significantly higher concentrations than before. The researchers produce the pathogens in cell cultures in small bioreactors.
By operating in a regulatory blind spot, DIYers could upset the status quo for drug production.
There is little financial incentive for pharmaceutical companies to bring vaccines to the market.
China's drug regulator has ordered Changchun Changsheng Life Sciences Limited to stop production and launched an investigation into the company over illegal production of rabies vaccines for human use.
Machine-learning model could help chemists make molecules with higher potencies, much more quickly.
A new UK-funded project, the Future Vaccine Manufacturing Hub, is trying a new model that will include a faster process for finding and testing vaccines alongside localized pop-up factories that can get large supplies of vaccines to people within weeks of a threat having been identified.